Skip to main content

Nastech Licenses RNAi Patents from Carnegie Institution

NEW YORK, Feb. 2 (GenomeWeb News) - Nastech Pharmaceutical Company has licensed RNA interference patents and patent applications from the Carnegie Institution of Washington, the company said today.

 

The worldwide, non-exclusive license covers small interfering RNA technology, including U.S. Patent 6,506,559 B1. Nastech plans to use the technology in tight junction research and to develop therapeutics.

 

Nastech, based in Bothell, Wash., is developing methods to deliver drugs through the nose.

 

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.